Some European countries take more than twice as long as others to reach health technology assessment decisions to reimburse new cancer drugs following their approval by the European Medicines Agency.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
